1. Home
  2. IDAI vs ACXP Comparison

IDAI vs ACXP Comparison

Compare IDAI & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IDAI
  • ACXP
  • Stock Information
  • Founded
  • IDAI 2016
  • ACXP 2017
  • Country
  • IDAI United States
  • ACXP United States
  • Employees
  • IDAI N/A
  • ACXP N/A
  • Industry
  • IDAI Computer Software: Prepackaged Software
  • ACXP Biotechnology: Pharmaceutical Preparations
  • Sector
  • IDAI Technology
  • ACXP Health Care
  • Exchange
  • IDAI Nasdaq
  • ACXP Nasdaq
  • Market Cap
  • IDAI 7.7M
  • ACXP 9.1M
  • IPO Year
  • IDAI N/A
  • ACXP 2021
  • Fundamental
  • Price
  • IDAI $2.86
  • ACXP $4.45
  • Analyst Decision
  • IDAI
  • ACXP Strong Buy
  • Analyst Count
  • IDAI 0
  • ACXP 3
  • Target Price
  • IDAI N/A
  • ACXP $143.67
  • AVG Volume (30 Days)
  • IDAI 25.9K
  • ACXP 88.7K
  • Earning Date
  • IDAI 08-14-2025
  • ACXP 08-12-2025
  • Dividend Yield
  • IDAI N/A
  • ACXP N/A
  • EPS Growth
  • IDAI N/A
  • ACXP N/A
  • EPS
  • IDAI N/A
  • ACXP N/A
  • Revenue
  • IDAI $3,366,415.00
  • ACXP N/A
  • Revenue This Year
  • IDAI $25.13
  • ACXP N/A
  • Revenue Next Year
  • IDAI $48.09
  • ACXP N/A
  • P/E Ratio
  • IDAI N/A
  • ACXP N/A
  • Revenue Growth
  • IDAI N/A
  • ACXP N/A
  • 52 Week Low
  • IDAI $1.43
  • ACXP $3.80
  • 52 Week High
  • IDAI $18.75
  • ACXP $44.90
  • Technical
  • Relative Strength Index (RSI)
  • IDAI 50.28
  • ACXP 38.08
  • Support Level
  • IDAI $2.85
  • ACXP $4.40
  • Resistance Level
  • IDAI $3.06
  • ACXP $7.15
  • Average True Range (ATR)
  • IDAI 0.17
  • ACXP 0.61
  • MACD
  • IDAI 0.00
  • ACXP 0.15
  • Stochastic Oscillator
  • IDAI 50.63
  • ACXP 30.15

About IDAI T Stamp Inc.

T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The artificial intelligence-powered solutions segment generates revenue principally from software licenses, professional services, and recurring Software-as-a-Service ("SaaS") revenue.

About ACXP Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.

Share on Social Networks: